TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04015479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Protein Powder
Description: Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
Study: NCT02706600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: myCOPD
Description: myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written Self management plan
Description: The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
Study: NCT03361917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Description: Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
Study: NCT04474288

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody testing
Description: venipuncture for SARS-CoV-2 IgG

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody testing
Description: venipuncture for SARS-CoV-2 IgG
Study: NCT03091400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Study: NCT00243282

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Response (instruction, pocket practice card prov)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness training using model developed from UMass
Study: NCT02686710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT03932747

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pre- Hydratión skin
Description: Measurement of hydration of the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre- Hydratión skin
Description: Measurement of hydration of the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre- Hydratión skin
Description: Measurement of hydration of the skin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: post- Hydratión skin
Description: Measurement of hydration of the skin.
Study: NCT05902715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral implant placement with socket shield technique
Description: tooth is split in socket shield configuration, implant is immediately placed
Study: NCT01173393

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: PARAMEDIC COOLING
Description: For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg.
Study: NCT02121847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05% ophthalmic emulsion
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose-based lubricant eye drops
Description: Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Study: NCT02169908

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotest

Intervention type: DEVICE
Group type: OTHER
Intervention: von Frey hairs
Study: NCT05794854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal aerobic endurance exercise
Description: Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control training intervention
Description: Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
Study: NCT03547661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P-Dragees rosa Lichtenstein
Description: Placebo dragées

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P-Dragees rosa Lichtenstein
Description: Placebo dragées
Study: NCT03729219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli ETVAX
Description: Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT04135053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised Neisseria lactamica
Description: Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
Study: NCT03585647

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
Study: NCT03932747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post- Hydratión skin
Description: Measurement of hydration of the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post- Hydratión skin
Description: Measurement of hydration of the skin.
Study: NCT04087759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.
Study: NCT02377284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photograph
Description: Add a photograph to a chef card.
Study: NCT01242332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 75 mg po 2 hrs before surgery
Study: NCT03816956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-301
Description: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04209244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eskimo-3 Pure Fish Oil
Description: Dosage: 10 ml/day (2.6 g EPA+DHA)
Study: NCT04087759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.
Study: NCT03397589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) services
Description: CHWs are non-clinical people who provide education, care coordination, and support to families.
Study: NCT02361099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by SENTINEL application
Description: Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
Study: NCT04209244

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rapeseed Oil
Description: Dosage: 10 ml/day (0 g EPA+DHA)
Study: NCT01731574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miconazole
Study: NCT01179139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
Study: NCT03478774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 70l/min
Description: HFNCT will be provided using OptiFlow by Fisher\&Paykel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 70l/min
Description: HFNCT will be provided using OptiFlow by Fisher\&Paykel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 10 l/min
Description: Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 2l/min
Description: Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Description: Continuous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Description: Continuous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Description: Continuous

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: Continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen 0.25l/min
Description: 0.25l/min of oxygen via an endotracheal tube
Study: NCT02017535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
Study: NCT01336309

Intervention type: BEHAVIORAL
Intervention: Yoga Research Tool
Description: We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.

Intervention type: BEHAVIORAL
Intervention: Yoga Research Tool
Description: We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.

Intervention type: BEHAVIORAL
Intervention: Yoga Research Tool
Description: We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.

Intervention type: BEHAVIORAL
Intervention: Yoga Research Tool
Description: We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
Study: NCT02067585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lipid meals
Description: Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lipid meals
Description: Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lipid meals
Description: Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
Study: NCT05155072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903
Study: NCT03695783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online decision aid called IBD&me
Description: Patients randomized to IBD\&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized educational material
Description: Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
Study: NCT05155072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2
Study: NCT03985618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of Labour
Description: Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of Labour
Description: Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
Study: NCT03359980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transfer
Description: transfer of fecal microbiota from healthy donors to the patients
Study: NCT01672632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding
Description: We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
Study: NCT00506961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
Study: NCT02311179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis, BoneMaster-Exceed cup (Biomet)
Description: Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis Exceed cup without HA (Biomet)
Description: Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
Study: NCT02293187

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
Study: NCT01410448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
Study: NCT05155072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2
Study: NCT04238780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
Study: NCT01410448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.